Opioid withdrawalMANAGEMENT

TOXICOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

642 items

☷ Legend

01Approach to the Critical Patient/attcp77

Stabilization priorities

›Immediate threats

›Airway compromise from emesis or sedation

›Lateral positioning and suction readiness

›Consider naloxone only if ongoing opioid toxicity suspected

›Severe dehydration

›Persistent vomiting

›Profuse diarrhoea

›Hemodynamic instability

›Hypotension from volume loss or alpha-2 agonists

›Tachyarrhythmia from withdrawal or stimulants

›Hyperthermia

›Consider stimulant intoxication or sepsis if marked

›Monitoring and environment

›Cardiorespiratory monitoring for severe symptoms

›Continuous pulse oximetry

›Cardiac monitoring if QT prolongation risk or methadone use

›Intravenous access when moderate to severe withdrawal or poor oral intake

›Crystalloid rehydration targets guided by vitals and urine output

›High risk features needing escalation

›Altered mental status not explained by withdrawal

›Consider head injury, infection, metabolic, co-ingestants

›Chest pain or dyspnea

›Consider ACS, PE, pneumonia, stimulant toxicity

›Severe abdominal pain

›Consider withdrawal mimics and surgical pathology

›Pregnancy

›Obstetric consultation trigger for moderate to severe withdrawal

›Polysubstance withdrawal risk

›Alcohol withdrawal history

›Benzodiazepine dependence history

Key concepts

›Core physiology

›Opioid withdrawal is adrenergic hyperactivity after mu receptor downregulation

›Autonomic symptoms predominate

›Symptoms are rarely life-threatening but complications can be

›Opioid withdrawal severity correlates with dependence level and opioid half-life

›Short-acting opioids earlier onset

›Long-acting opioids later onset

›Time course patterns

›Short-acting opioids

›Onset 6-12 hours after last use

›Peak 24-72 hours

›Duration 5-10 days

›Long-acting opioids and methadone

›Onset 24-48 hours or longer

›Peak 3-5 days

›Duration 10-20 days

›Buprenorphine cessation

›Delayed onset

›Prolonged lower-grade symptoms

Initial decision points

›Syndrome classification

›Withdrawal versus intoxication

›Withdrawal findings

›Mydriasis

›Diaphoresis

›Piloerection

›Tachycardia

›Intoxication findings

›Miosis

›Bradypnea

›Sedation

›Withdrawal versus mimic

›Gastroenteritis

›Fever or infectious exposure

›Sepsis

›Persistent hypotension

›Thyrotoxicosis

›Tremor with weight loss and goitre

›Treatment pathway choice

›Opioid agonist pathway preferred for OUD and significant withdrawal

›Buprenorphine based initiation

›Methadone based initiation when buprenorphine not feasible

›Non-opioid symptomatic pathway

›Alpha-2 agonist

›Supportive medications

›Micro-induction pathway

›High fentanyl exposure

›Prior precipitated withdrawal history

02History/hx82

Focused withdrawal and OUD history

›Opioid exposure profile

›Substance type

›Heroin

›Fentanyl or analog exposure

›Prescription opioids

›Methadone

›Buprenorphine

›Route

›Oral

›Intranasal

›Smoked

›Injection

›Last use timing

›Hours since last use

›Typical dosing interval

›Tolerance level

›Daily amount estimate

›Escalation over time

›Withdrawal phenotype

›Symptom onset relative to last use

›Early onset suggests short-acting opioids

›Delayed onset suggests long-acting opioids

›Predominant symptoms

›GI symptoms

›Myalgias and bone pain

›Anxiety and insomnia

›Autonomic symptoms

›Prior treatment response

›Buprenorphine history

›Prior induction success

›Prior precipitated withdrawal

›Methadone history

›Current OTP enrolment

›Last observed dose

›Naltrexone history

›Recent oral or extended-release use

›Co-ingestants and concurrent withdrawal risk

›Alcohol use pattern

›Prior seizures or delirium tremens

›Benzodiazepines or Z-drugs

›Daily use

›Abrupt cessation risk

›Stimulants

›Cocaine

›Methamphetamine

›Sedatives

›Gabapentinoids

›Clonidine use

›Complication risk

›Dehydration risk factors

›Poor oral intake

›Persistent emesis

›Infectious risks

›Injection drug use

›Fever or rigors

›Recent skin infection

›Psychiatric and safety risks

›Severe agitation

›Psychosis symptoms

›Social and harm reduction context

›Housing stability

›Access to follow-up

›Access to naloxone

›Recent overdose events

Medication and medical history

›Comorbidities

›Respiratory disease

›Sleep apnea

›COPD

›Cardiac disease

›Baseline bradycardia

›QT prolongation history

›Liver disease

›Hepatitis C

›Cirrhosis

›Renal disease

›Current medications

›QT prolonging drugs

›Antihypertensives

›CNS depressants

›Pregnancy and lactation status

›Pregnancy possibility

›Breastfeeding

03Physical Exam/exam51

Withdrawal severity and complications

›Withdrawal signs

›Pupillary size

›Mydriasis

›Autonomic findings

›Diaphoresis

›Piloerection

›Lacrimation

›Rhinorrhea

›Neuromuscular findings

›Tremor

›Restlessness

›Yawning

›GI findings

›Abdominal cramping

›Vomiting

›Diarrhoea

›Hydration status

›Mucous membranes

›Orthostatic vitals

›Capillary refill

›Vital sign interpretation

›Tachycardia and hypertension consistent with withdrawal

›Consider stimulant intoxication if extreme

›Hypotension

›Volume depletion

›Alpha-2 agonist effect

›Sepsis consideration

›Fever

›Infection evaluation trigger

›Mental status and behavioural state

›Agitation level

›Anxiety severity

›Hallucinations or delirium

›Consider alternative diagnosis or other withdrawal

Focused exam for alternate diagnoses

›Cardiopulmonary

›Work of breathing

›Wheeze or crackles

›Chest wall tenderness

›Abdomen

›Focal peritonism

›Distension

›Skin and soft tissue

›Injection sites

›Abscess

›Cellulitis

›Endocarditis screen

›New murmur

›Peripheral stigmata

›Neurologic screen

›Focal deficits

›Head trauma signs

04Differential Diagnosis/ddx32

Life-threatening and important mimics

›Opioid intoxication or mixed toxidrome

›ICD-10 T40.2X1A poisoning by other opioids accidental

›Bradyrespnea and miosis

›Alcohol withdrawal

›ICD-10 F10.239 alcohol dependence with withdrawal

›Tremor with autonomic instability and hallucinosis risk

›Benzodiazepine withdrawal

›ICD-10 F13.239 sedative dependence with withdrawal

›Seizure risk

›Sepsis

›ICD-10 A41.9 sepsis unspecified organism

›Fever with persistent hypotension

›Acute gastroenteritis

›Infectious exposure and fever

›Thyrotoxicosis

›Tachycardia and tremor with weight loss

›Acute coronary syndrome

›Withdrawal related demand ischemia possible

›Pulmonary embolism

›Dyspnea and pleuritic pain

›Diabetic ketoacidosis

›Polyuria, polydipsia, ketones, metabolic acidosis

Related opioid conditions

›Opioid use disorder

›ICD-10 F11.20 opioid dependence uncomplicated

›SNOMED CT opioid dependence

›Opioid withdrawal

›ICD-10 F11.23 opioid dependence with withdrawal

›SNOMED CT opioid withdrawal

›Opioid induced hyperalgesia

›Diffuse pain disproportionate to exam

›Opioid related constipation and ileus

›Abdominal distension and reduced bowel sounds

05Laboratory Tests/lt45

Core tests by presentation

›Baseline safety labs

›Electrolytes

›Sodium

›Potassium

›Chloride

›Bicarbonate

›Renal function

›Creatinine

›eGFR

›Glucose

›Hypoglycaemia mimic check

›Liver panel when hepatic disease or medication planning

›ALT

›AST

›Bilirubin

›Dehydration and GI loss workup

›Magnesium

›Arrhythmia risk when low

›Phosphate

›Malnutrition risk marker

›Pregnancy testing

›Serum or urine beta hCG for pregnancy possibility

›Treatment pathway modification

›Infection evaluation when indicated

›CBC

›Leukocytosis interpretation in context

›Blood cultures when sepsis concern

›CRP as adjunct only

›Substance related testing when useful

›Urine drug screen limits

›Limited fentanyl detection in some assays

›Does not quantify intoxication severity

›Confirmatory testing context

›Clinical decision making should not depend on delayed results

Targeted labs for medication safety

›QT risk pathway

›Electrolyte abnormalities

›Potassium repletion threshold local protocol

›Magnesium repletion threshold local protocol

›Baseline ECG preferred before methadone or lofexidine when feasible

›Hepatic impairment pathway

›Child-Pugh context when known cirrhosis

›Lofexidine dose reduction required in moderate to severe hepatic impairment

›Renal impairment pathway

›eGFR staging

›Lofexidine dose reduction required when eGFR reduced

06Diagnostic Tests/dt51

Scoring Systems

›Withdrawal severity tools

›Clinical Opiate Withdrawal Scale COWS

›11 item clinician rated scale

›Score interpretation

›5-12 mild

›13-24 moderate

›25-36 moderately severe

›More than 36 severe

›Buprenorphine standard induction timing

›Objective withdrawal before first dose

›Moderate withdrawal threshold commonly used

›Subjective Opiate Withdrawal Scale SOWS

›Patient reported symptom burden

›Use as adjunct to COWS when communication barriers

›Sedation and respiratory risk tools

›Richmond Agitation Sedation Scale when mixed picture

›Respiratory rate and end tidal CO2 when opioid toxicity concern

MRI

›Neuroimaging indications

›Persistent altered mental status

›Consider structural lesion

›Focal neurologic deficit

›Stroke or abscess consideration

›Spine imaging indications

›Back pain with fever in injection drug use

›Epidural abscess consideration

›Practical limitations

›Agitation limiting MRI tolerance

›Time to MRI delaying treatment decisions

›Head CT indications

›Head trauma with altered mental status

›Anticoagulation use with trauma

›CT abdomen indications

›Focal peritonism

›Severe abdominal pain out of proportion to typical withdrawal

›CT pulmonary angiography considerations

›Dyspnea with hypoxia not explained by withdrawal

›Interpretation pitfalls

›Withdrawal tachycardia does not exclude PE or sepsis

›Over attribution of symptoms to withdrawal

Ultrasound

›Point of care echocardiography

›Shock evaluation

›Volume status

›Pericardial effusion

›Endocarditis adjunct

›Limited sensitivity for vegetations

›Soft tissue ultrasound

›Abscess identification

›Drainage planning

›Cellulitis versus abscess differentiation

›Obstetric ultrasound

›Pregnancy confirmation when unclear and beta hCG positive

07Disposition/dispo35

Level of care selection

›Discharge appropriate when stable and resources available

›Mild withdrawal controlled with oral therapy

›Able to tolerate oral intake

›Reliable follow-up within 24-72 hours

›Initiated medication for OUD or arranged rapid access

›Observation or short stay appropriate

›Moderate withdrawal requiring induction monitoring

›Recent fentanyl exposure with precipitated withdrawal risk

›Persistent vomiting requiring IV fluids

›Admission indications

›Severe withdrawal with complications

›Refractory dehydration

›Electrolyte derangements

›Serious comorbidity

›Significant cardiac disease

›Respiratory failure risk

›Suspected infection requiring IV therapy

›Concurrent high risk withdrawal

›Alcohol withdrawal risk

›Benzodiazepine withdrawal risk

›Pregnancy with moderate to severe withdrawal

›Transfer indications

›Need for opioid treatment program services not available

›Higher level monitoring requirement

›Obstetric or neonatal services requirement

Follow-up and linkage

›Rapid access addiction clinic referral

›Next day pathway when possible

›Pharmacy led induction follow-up when available

›Primary care linkage

›Buprenorphine prescribing follow-up

›Chronic pain coordination when relevant

›Harm reduction supports

›Naloxone supply

›Safer use counselling

›Needle and syringe program referral

08Treatment/t149

Treatment goals and principles

›Primary goals

›Symptom relief

›Control autonomic symptoms

›Control GI losses

›Prevention of return to use and overdose

›Initiation of medication for OUD preferred

›Education on reduced tolerance after abstinence

›Treatment of complications

›Dehydration correction

›Infection treatment when present

›First line strategy for OUD and moderate to severe withdrawal

›Buprenorphine or methadone recommended over alpha-2 agonist alone

›Better withdrawal symptom control

›Better retention in withdrawal management

Buprenorphine standard induction

›Preconditions

›Objective withdrawal present

›COWS consistent with at least moderate severity

›Last opioid timing compatible with withdrawal

›Short-acting opioid elapsed interval usually adequate

›Methadone or long-acting opioid needs longer interval

›Avoidance of precipitated withdrawal risk

›Fentanyl exposure increases risk

›Partial agonist high affinity displaces full agonist

›Day 1 dosing

›Buprenorphine sublingual 2-4 mg initial dose

›Reassess after 30-60 minutes

›Additional 2-8 mg based on symptoms

›Typical day 1 total 8-16 mg

›Higher total sometimes required with high tolerance

›Day 2 and maintenance

›Total daily dose based on day 1 response

›Common maintenance 12-24 mg daily

›Split dosing option early

›Twice daily dosing for symptom coverage

›Monitoring and safety

›Sedation risk increased with other CNS depressants

›Alcohol

›Benzodiazepines

›Respiratory depression uncommon when used alone

›Risk increases with polysubstance use

›Evidence and guideline notes

›ASAM 2020 focused update supports initiation after objective withdrawal signs

›Initial dose 2-4 mg with titration in 2-8 mg increments

Buprenorphine micro-induction and special induction strategies

›Indications

›High fentanyl exposure with repeated precipitated withdrawal

›Unable to tolerate abstinence interval

›Transition from methadone when taper not feasible

›Micro-induction principles

›Very low dose buprenorphine while continuing full agonist briefly

›Gradual receptor occupancy increase

›Lower precipitated withdrawal risk

›Close follow-up required

›Daily contact plan

›Clear escalation instructions

›ED focused high dose induction considerations

›Persistent moderate to severe symptoms after standard titration

›Additional dosing in monitored setting

›Observation for sedation and hypotension

›Polysubstance use screening

Methadone pathway

›Indications

›Buprenorphine contraindication or failure

›Patient preference with informed consent

›High opioid tolerance with poor buprenorphine response

›Regulatory and access constraints

›Opioid treatment program requirements vary by jurisdiction

›Hospital based initiation pathways depend on local policy

›Withdrawal management dosing guidance

›Initial dose typically 20-30 mg daily for short-acting opioid withdrawal management

›Taper over approximately 6-10 days when detoxification goal

›Dose increases for maintenance are slower

›Increases no more than 10 mg about every 5 days based on symptoms or sedation

›Safety monitoring

›QT prolongation risk

›Baseline ECG when feasible

›Electrolyte correction

›Sedation and respiratory depression risk

›Higher with benzodiazepines and alcohol

›Evidence and guideline notes

›ASAM 2020 supports methadone for OUD with careful monitoring and individualized titration

Alpha-2 adrenergic agonists

›Role

›Symptom mitigation option when opioid agonist therapy declined or not available

›Adjunct to opioid agonist therapy for autonomic symptoms

›Lofexidine

›Indication

›Mitigation of opioid withdrawal symptoms in adults

›Dosing

›Starting dosage 0.54 mg orally four times daily

›3 tablets of 0.18 mg per dose

›5-6 hours between doses

›Maximum total daily dose 2.88 mg

›Maximum single dose 0.72 mg

›Typical peak withdrawal use first 5-7 days

›Treatment up to 14 days guided by symptoms

›Discontinuation taper over 2-4 days

›Reduce by 1 tablet per dose every 1-2 days

›Dose adjustments

›Hepatic impairment

›Moderate impairment 0.36 mg four times daily

›Severe impairment 0.18 mg four times daily

›Renal impairment

›eGFR 30-89.9 dose 0.36 mg four times daily

›eGFR less than 30 dose 0.18 mg four times daily

›Adverse effects

›Hypotension and orthostasis

›Bradycardia

›Sedation

›QT prolongation

›Clonidine off-label

›Typical oral dosing

›0.1 mg orally every 6-8 hours as needed

›Titrate based on symptoms and blood pressure

›Hold parameters for hypotension and bradycardia per local protocol

›Transdermal option

›Patch for adherence support in selected patients

›Adverse effects

›Hypotension

›Bradycardia

›Rebound hypertension with abrupt cessation

Symptom targeted supportive medications

›Fluids and electrolytes

›Oral rehydration when tolerated

›IV crystalloid when persistent vomiting or dehydration

›Electrolyte replacement based on labs

›Nausea and vomiting

›Ondansetron orally or IV per local protocol

›Metoclopramide alternative when appropriate

›Diarrhoea

›Loperamide when no infectious red flags

›Avoid if concern for toxic megacolon or severe infection

›Abdominal cramping

›Dicyclomine when appropriate

›Myalgias and arthralgias

›Acetaminophen dosing per local protocol

›NSAID dosing per local protocol when no contraindication

›Anxiety and insomnia

›Hydroxyzine as non-benzodiazepine option

›Trazodone or doxepin low dose options depending on setting

›Avoid new benzodiazepine initiation in most cases

›Restlessness and akathisia like symptoms

›Gabapentin use varies by local policy

›Misuse potential counselling

›Autonomic symptoms

›Alpha-2 agonist adjunct

›Cooling measures for diaphoresis

Treatments to avoid or use with caution

›Ultra-rapid opioid detoxification with anesthesia

›Not recommended due to high risk of adverse events and death

›Opioid agonist plus sedatives without monitoring

›Increased respiratory depression risk

›Antidiarrheals masking infection

›Fever or bloody stool as red flags

09Special Populations/sp35

Pregnancy

›Maternal fetal considerations

›Untreated withdrawal associated with relapse risk and physiologic stress

›Medication for OUD preferred over detoxification in most cases

›Medication selection

›Methadone and buprenorphine as standard options in guidelines

›Coordination with obstetrics and addiction care

›Avoid naltrexone initiation during acute withdrawal in pregnancy

›Induction considerations

›Close monitoring during initiation

›Volume status

›Fetal assessment when viable gestation

›Breastfeeding considerations

›Buprenorphine and methadone compatible in many cases

›Individualized assessment and counselling

Geriatric

›Physiologic risks

›Higher sensitivity to hypotension

›Alpha-2 agonist dose caution

›Higher fall risk with sedation

›Avoid polypharmacy

›Comorbidity burden

›Cardiac conduction disease

›ECG consideration with methadone or lofexidine

›Renal impairment

›Lofexidine dose reduction based on eGFR

›Disposition bias

›Lower threshold for observation or admission when frail

Pediatrics

›Scope note

›Most opioid withdrawal management guidance applies to adolescents and adults

›Neonatal abstinence syndrome is separate pathway

›Adolescent considerations

›Confidentiality and consent laws vary by jurisdiction

›Family involvement when safe and appropriate

›Medication safety

›Lofexidine safety not established in children per prescribing information

›Buprenorphine use follows local regulatory approvals and specialist guidance

10Background/b32

Epidemiology

›Opioid withdrawal context

›Withdrawal occurs in opioid dependence after reduction or cessation

›Fentanyl era increases complexity of induction timing and precipitated withdrawal risk

›OUD burden

›High morbidity and mortality from overdose

›Medication for OUD reduces mortality and improves retention

Pathophysiology

›Neuroadaptation

›Chronic opioid exposure downregulates endogenous opioid tone

›Locus coeruleus adrenergic hyperactivity during withdrawal

›Clinical manifestations

›Autonomic hyperactivity

›Sweating

›Tachycardia

›Hypertension

›GI hypermotility

›Diarrhoea

›Cramping

›Central symptoms

›Anxiety

›Insomnia

›Precipitated withdrawal mechanism

›Buprenorphine high receptor affinity displaces full agonist

›Rapid net decrease in agonism triggers abrupt symptoms

Therapeutic Considerations

›Opioid agonist therapy rationale

›Buprenorphine partial agonism suppresses withdrawal and cravings

›Methadone full agonism suppresses withdrawal and cravings

›Alpha-2 agonist rationale

›Reduces adrenergic symptoms

›Does not treat cravings or OUD core pathology

›Outcome considerations

›Detoxification without ongoing MOUD associated with high relapse and overdose risk

›Reduced tolerance after abstinence increases overdose risk if return to use

11Patient Discharge Instructions/pdi35

copy discharge instructions

›Key messages

›Reduced tolerance after withdrawal increases overdose risk

›Avoid using alone

›Avoid mixing opioids with alcohol or benzodiazepines

›Medication instructions

›Buprenorphine dosing plan

›Daily dose schedule provided

›Missed dose instructions provided

›Symptom medications

›Antiemetic plan

›Antidiarrheal plan with red flags

›Naloxone and overdose response

›Naloxone kit provided or prescription arranged

›Overdose signs

›Slow or stopped breathing

›Blue lips or nails

›Cannot wake up

›Emergency response

›Call emergency services immediately

›Rescue breathing if trained

›Return to ED now

›Chest pain

›Trouble breathing

›Fainting or severe dizziness

›Confusion or severe drowsiness

›Persistent vomiting with inability to keep fluids down

›Fever

›Severe abdominal pain

›Signs of skin infection

›Spreading redness

›Pus

›Follow-up plan

›Addiction medicine clinic appointment details

›Primary care follow-up within 1 week

›Local support resources contact information

12References/r18

Clinical guidelines and key sources

›ASAM National Practice Guideline for the Treatment of Opioid Use Disorder 2020 Focused Update

›Buprenorphine initiation after objective signs of withdrawal

›Initial buprenorphine 2-4 mg with titration in 2-8 mg increments

›Alpha-2 agonists effective but less effective than buprenorphine or methadone for retention

›Ultra-rapid opioid detoxification not recommended due to adverse events and death risk

›SAMHSA TIP 63 Medications for Opioid Use Disorder 2021

›MOUD as evidence-based standard for OUD

›Pregnancy and parenting considerations

›Clinical Opiate Withdrawal Scale COWS Wesson and Ling 2003 tool and derivatives

›Severity thresholds 5-12 mild 13-24 moderate 25-36 moderately severe more than 36 severe

›Lofexidine tablets prescribing information 2024

›Starting dosage 0.54 mg orally four times daily

›Maximum total daily dose 2.88 mg

›Dose adjustment for hepatic and renal impairment

›QT prolongation and hypotension warnings

›Canadian guidance resources

›CRISM National Opioid Use Disorder Guideline November 2024

›Health Canada substance use help and referral resources updated 2025

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.